NovoCure Ltd

038

Company Profile

  • Business description

    NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.

  • Contact

    Grenville Street
    No. 4 The Forum, Second Floor
    St. HelierJE2 4UF
    JEY

    T: +44 1534756700

    E: [email protected]

    https://www.novocure.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Medical Devices

    Fiscal Year End

    31 December 2026

    Employees

    1,605

Stocks News & Analysis

stocks

AI lands a blow on some Aussie stocks – yet stands to benefit others

AI is reshaping ASX tech moats - but some are more insulated than others.
stocks

This might be the best core stock bargain in the US market today

Patient investors should consider building a position in this wide-moat stock while it’s seriously undervalued.
stocks

Data center demand drives strong earnings outlook for SGM

Sims guides huge earnings upgrade as data center metals demand spikes.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,552.60110.50-1.28%
CAC 407,511.59154.03-2.01%
DAX 4021,893.00487.19-2.18%
Dow JONES (US)45,577.47443.96-0.96%
FTSE 1009,686.63376.87-3.74%
HKSE24,382.471,118.11-4.38%
NASDAQ21,647.61443.08-2.01%
Nikkei 22551,515.491,857.04-3.48%
NZX 50 Index12,899.72151.89-1.16%
S&P 5006,506.48100.01-1.51%
S&P/ASX 2008,365.90106.40-1.26%
SSE Composite Index3,813.28143.77-3.63%

Market Movers